Drug Delivery Systems for Cell & Gene Therapy

Sixfold Bioscience is pioneering advancements in RNA delivery systems, addressing a significant challenge in RNA therapeutics: the limited ability to target various cell types beyond the liver. Their innovative approach leverages insights from nature, recognizing that over 99% of RNA is delivered without encapsulation in lipidic carriers. By studying natural RNA delivery mechanisms, the company has developed Mergo®, a programmable RNA tag that encodes modifications to influence the destination of RNA therapeutics. This method allows for a more effective and biologically harmonious delivery system, moving away from traditional encapsulation methods.

The Mergo® platform is further enhanced by the integration of artificial intelligence and machine learning, enabling the design of a vast library of over 100,000 unique Mergos. This extensive library facilitates rapid optimization and selection of RNA delivery solutions tailored to specific therapeutic needs. The platform employs automated processes and intelligent experimental designs to streamline the production and testing of these Mergos, allowing for high-throughput experimentation. This innovative combination of evolutionary principles and computational power positions Sixfold Bioscience at the forefront of RNA therapeutic development, promising to revolutionize the field by enabling targeted delivery to a broader range of cell types.

United Kingdom

Develop safe and effective drug delivery systems for cell andgene therapeutics.

Cancer

Sixfold Bioscience

Europe - West

Sixfold Bioscience

Company Details